Puma Biotechnology (PBYI) Net Income towards Common Stockholders: 2017-2024
Historic Net Income towards Common Stockholders for Puma Biotechnology (PBYI) over the last 8 years, with Dec 2024 value amounting to $23.2 million.
- Puma Biotechnology's Net Income towards Common Stockholders fell 56.47% to $8.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.9 million, marking a year-over-year increase of 28.66%. This contributed to the annual value of $23.2 million for FY2024, which is 7.47% up from last year.
- Puma Biotechnology's Net Income towards Common Stockholders amounted to $23.2 million in FY2024, which was up 7.47% from $21.6 million recorded in FY2023.
- Over the past 5 years, Puma Biotechnology's Net Income towards Common Stockholders peaked at $23.2 million during FY2024, and registered a low of -$60.0 million during FY2020.
- Its 3-year average for Net Income towards Common Stockholders is $14.9 million, with a median of $21.6 million in 2023.
- Data for Puma Biotechnology's Net Income towards Common Stockholders shows a peak YoY surged of 1,079,450.00% (in 2023) over the last 5 years.
- Puma Biotechnology's Net Income towards Common Stockholders (Yearly) stood at -$60.0 million in 2020, then skyrocketed by 51.45% to -$29.1 million in 2021, then soared by 100.01% to $2,000 in 2022, then surged by 1,079,450.00% to $21.6 million in 2023, then rose by 7.47% to $23.2 million in 2024.